Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension

Chest

Volumn 124, Issue 4, 2003, Pages 1294-1304

  Olschewski, Horst ^a,e   Rohde, Beate ^b   Behr, Jürgen ^c   Ewert, Ralph ^d   Gessler, Tobias ^a   Ghofrani, H Ardeschir ^a   Schmehl, Thomas ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^e UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Iloprost; Nebulization device; Pulmonary hypertension

Indexed keywords

ILOPROST; PROSTACYCLIN DERIVATIVE;

ADULT; AEROSOL; AGED; AREA UNDER THE CURVE; ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MULTICENTER STUDY; NEBULIZER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SWAN GANZ CATHETER; VASODILATATION; VENOUS OXYGEN TENSION;

EID: 0142074258     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.4.1294     Document Type: Article

References (26)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349
2. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
3. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434
4. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865
5. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740-743
6. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409-415
7. Agusti AG, Rodriguez-Roisin R. Effect of pulmonary hypertension on gas exchange. Eur Respir J 1993; 6:1371-1377
8. Walmrath D, Schneider T, Pilch J, et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342:961-962
9. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160:600-607
10. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384-389
11. Warren JB, Higenbottam T. Caution with use of inhaled nitric oxide. Lancet 1996; 348:629-630
12. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH Study Group. J Am Coll Cardiol 2000; 35:176-182
13. Miller OI, Tang SF, Keech A, et al. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346:51-52
14. Cueto E, Lopez-Herce J, Sanchez A, et al. Life-threatening effects of discontinuing inhaled nitric oxide in children. Acta Paediatr 1997; 86:1337-1339
15. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
16. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
17. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-824
18. Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000; 101:2388-2392
19. Olschewski H, Ghofrani HA, Walmrath D, et al. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998; 24:631-634
20. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132:435-443
21. Nikkho S, Seeger W, Baumgartner R, et al. One-year observation of iloprost therapy in patients with pulmonary hypertension [abstract]. Eur Respir J 2001; 18(suppl 33):324s
22. Roth C, Heyder J, Wagner T, et al. In vitro characterization of ilomedin inhalation devices [abstract]. J Aerosol Med 1999; 12:98
23. Rich S. Primary pulmonary hypertension. Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France; September 6-10, 1998
24. Hildebrand M, Krause W, Angeli P, et al. Pharmacokinetics of iloprost in patients with hepatic dysfunction. Int J Clin Pharmacol Ther Toxicol 1990; 28:430-434
25. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986; 30:61-68
26. Schermuly RT, Schulz A, Ghofrani HA, et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J Pharmacol Exp Ther 2002; 303:741-745